An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly reported new Phase 3b clinical trial results saying that using two of its drugs together — Taltz (ixekizumab) and Zepbound (tirzepatide) — led to better and lasting results after one year for adults who have psoriatic disease and obesity. The company framed this as improved and durable efficacy, meaning the benefits held up over the 12-month study window. Taltz (ixekizumab) is a prescription medicine already used to treat psoriatic disease, which includes psoriasis (skin patches) and psoriatic arthritis (joint inflammation). It works by blocking a specific immune signaling protein that drives the inflammation seen in these conditions. Zepbound (tirzepatide) is a newer drug most people know for its effects on weight; it acts on hormone receptors that influence blood sugar, appetite, and weight. Together, the idea is to treat both the inflammatory disease and the metabolic condition of obesity at once. What the research actually shows, as reported, is that when these two drugs were given together in a Phase 3b trial, patients experienced better outcomes that were sustained through one year. A Phase 3b study typically tests effectiveness and safety in a somewhat broad, practical setting after earlier efficacy was shown, but it’s not the final regulatory step like a pivotal Phase 3 trial submission. The announcement doesn’t give exact numbers in the snippet you shared — so we don’t know how much better the results were, how many people were in the trial, or whether the improvements were mostly in skin symptoms, joint symptoms, weight loss, or all of these. Because those details aren’t provided here, we should be cautious about assuming the magnitude of benefit. This matters because many people with psoriatic disease also struggle with overweight or obesity, and the two problems can worsen each other. If a combined treatment truly improves skin and joint disease while also addressing weight, it could simplify care and improve overall health and quality of life for these patients. Clinicians, patients dealing with both conditions, and payers (insurers) would likely be the most interested groups, since combined benefits could change treatment choices. There are important caveats. The snippet is a company announcement, which can highlight positive findings without full context. We don’t have data on side effects, how many people stopped treatment, or whether any safety signals emerged from combining these drugs. Both medicines have known risks on their own: immune-targeting drugs can raise infection risk, and tirzepatide can cause gastrointestinal side effects and other metabolic effects. Also, regulatory approval for a combined indication would require full data review by authorities. Until the full study is published in a medical journal or reviewed by regulators, the real-world importance remains provisional. Bottom line: Lilly says combining Taltz and Zepbound helped patients with psoriatic disease and obesity over one year, but we need the full trial details and safety data to understand how meaningful and widely applicable that benefit really is.
Source: Eli Lilly and Company